Acquisition of docetaxel resistance in breast cancer cells reveals upregulation of ABCB1 expression as a key mediator of resistance accompanied by discrete upregulation of other specific genes and pathways
- PMID: 25596703
- DOI: 10.1007/s13277-015-3072-4
Acquisition of docetaxel resistance in breast cancer cells reveals upregulation of ABCB1 expression as a key mediator of resistance accompanied by discrete upregulation of other specific genes and pathways
Abstract
The microtubule-targeting taxanes are important in breast cancer therapy, but no predictive biomarkers have yet been identified with sufficient scientific evidence to allow clinical routine use. The purposes of the present study were to develop a cell-culture-based discovery platform for docetaxel resistance and thereby identify key molecular mechanisms and predictive molecular characteristics to docetaxel resistance. Two docetaxel-resistant cell lines, MCF7RES and MDARES, were generated from their respective parental cell lines MCF-7 and MDA-MB-231 by stepwise selection in docetaxel dose increments over 15 months. The cell lines were characterized regarding sensitivity to docetaxel and other chemotherapeutics and subjected to transcriptome-wide mRNA microarray profiling. MCF7RES and MDARES exhibited a biphasic growth inhibition pattern at increasing docetaxel concentrations. Gene expression analysis singled out ABCB1, which encodes permeability glycoprotein (Pgp), as the top upregulated gene in both MCF7RES and MDARES. Functional validation revealed Pgp as a key resistance mediator at low docetaxel concentrations (first-phase response), whereas additional resistance mechanisms appeared to be prominent at higher docetaxel concentrations (second-phase response). Additional resistance mechanisms were indicated by gene expression profiling, including genes in the interferon-inducible protein family in MCF7RES and cancer testis antigen family in MDARES. Also, upregulated expression of various ABC transporters, ECM-associated proteins, and lysosomal proteins was identified in both resistant cell lines. Finally, MCF7RES and MDARES presented with cross-resistance to epirubicin, but only MDARES showed cross-resistance to oxaliplatin. In conclusion, Pgp was identified as a key mediator of resistance to low docetaxel concentrations with other resistance mechanisms prominent at higher docetaxel concentrations. Supporting Pgp upregulation as one major mechanism of taxane resistance and cell-line-specific alterations as another, both MCF7RES and MDARES were cross-resistant to epirubicin (Pgp substrate), but only MDARES was cross-resistant to oxaliplatin (non-Pgp substrate).
Similar articles
-
The stepwise evolution of the exome during acquisition of docetaxel resistance in breast cancer cells.BMC Genomics. 2016 Jun 9;17:442. doi: 10.1186/s12864-016-2749-4. BMC Genomics. 2016. PMID: 27277198 Free PMC article.
-
Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines.BMC Cancer. 2016 Jan 22;16:34. doi: 10.1186/s12885-016-2071-1. BMC Cancer. 2016. PMID: 26801902 Free PMC article.
-
miRNA-34a is associated with docetaxel resistance in human breast cancer cells.Breast Cancer Res Treat. 2012 Jan;131(2):445-54. doi: 10.1007/s10549-011-1424-3. Epub 2011 Mar 12. Breast Cancer Res Treat. 2012. PMID: 21399894
-
Downregulation of histone H2A and H2B pathways is associated with anthracycline sensitivity in breast cancer.Breast Cancer Res. 2016 Feb 6;18(1):16. doi: 10.1186/s13058-016-0676-6. Breast Cancer Res. 2016. PMID: 26852132 Free PMC article. Clinical Trial.
-
Taxane resistance in breast cancer: mechanisms, predictive biomarkers and circumvention strategies.Cancer Treat Rev. 2012 Nov;38(7):890-903. doi: 10.1016/j.ctrv.2012.02.011. Epub 2012 Mar 31. Cancer Treat Rev. 2012. PMID: 22465195 Review.
Cited by
-
Comprehensive Analysis of Transcriptomics and Genetic Alterations Identifies Potential Mechanisms Underlying Anthracycline Therapy Resistance in Breast Cancer.Biomolecules. 2022 Dec 8;12(12):1834. doi: 10.3390/biom12121834. Biomolecules. 2022. PMID: 36551262 Free PMC article.
-
Prostate Tumor Overexpressed-1 (PTOV1) promotes docetaxel-resistance and survival of castration resistant prostate cancer cells.Oncotarget. 2017 Jul 22;8(35):59165-59180. doi: 10.18632/oncotarget.19467. eCollection 2017 Aug 29. Oncotarget. 2017. PMID: 28938627 Free PMC article.
-
Identifying clinically relevant drug resistance genes in drug-induced resistant cancer cell lines and post-chemotherapy tissues.Oncotarget. 2015 Dec 1;6(38):41216-27. doi: 10.18632/oncotarget.5649. Oncotarget. 2015. PMID: 26515599 Free PMC article.
-
The Role of TRIP6, ABCC3 and CPS1 Expression in Resistance of Ovarian Cancer to Taxanes.Int J Mol Sci. 2021 Dec 22;23(1):73. doi: 10.3390/ijms23010073. Int J Mol Sci. 2021. PMID: 35008510 Free PMC article.
-
Combined treatment with apatinib and docetaxel in A549 xenograft mice and its cellular pharmacokinetic basis.Acta Pharmacol Sin. 2018 Oct;39(10):1670-1680. doi: 10.1038/aps.2018.16. Epub 2018 May 17. Acta Pharmacol Sin. 2018. PMID: 29770798 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous